For example, treatment of chronic myeloid leukemia (CML) with the targeted agent imatinib fails due to acquired point mutations in the BCR-ABL kinase domain [3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.